secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001140361-26-013659
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed's brensocatib fails Phase 2b HS study; program discontinued
------------------------------------------------------------------

- Primary endpoint not met: AN count reduction 45.5% (10mg) and 40.3% (40mg) vs 57.1% placebo at Week 16.
- Secondary efficacy endpoints also not met; Insmed halts HS development of brensocatib.
- Safety consistent with prior studies; no new signals; 40mg dose well tolerated.
- Study enrolled 214 patients at 72 sites; 16-week placebo-controlled phase completed.
- Topline results will be presented at a future medical congress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126013659/0001140361-26-013659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126013659/ef20070042_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-013659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer